Tafinlar-Mekinist Combination Shows Significant Benefit in BRAF V600E/K Population

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Novartis published data from a phase III study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive advanced melanoma when treated with the first-line combination of Tafinlar (dabrafenib) and Mekinist (trametinib), compared to Tafinlar monotherapy.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login